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ABSTRACT
OBJECTIVE: The elucidation of the changes of fetuin-A in the context of bariatric surgery. 
DESIGN: Twenty obese patients (8 males, 12 females; body mass index = 42.5±3.4 kg/m2) were 
studied at baseline and 6 months after bariatric surgery. RESULTS: Serum fetuin-A levels did 
not differ with regard to the presence of each individual component of the Metabolic Syndrome 
(MetS) at baseline, except for hypertriglyceridaemia [increased serum fetuin-A levels (p=0.011)]. 
Circulating fetuin-A was positively correlated with serum triglycerides (TG) (r=0.461, p=0.047) 
and negatively correlated with serum globulins (r=-0.477, p=0.033) and C-reactive protein (CRP) 
(r=-0.604, p=0.010), while it independently predicted TG at baseline. Circulating fetuin-A did 
not change during the 6 months either in the whole population or in the subgroups of patients 
who were positive for each individual component of MetS at baseline and negative for this 
component at 6 months of follow-up, except for hypertriglyceridaemia [reduction of serum 
fetuin-A levels (p=0.046)]. The subgroup of patients with a decrease in circulating fetuin-A 
during the 6 months was characterized by a smaller reduction of serum globulins (p=0.003) 
and CRP (p=0.049). The change in serum fetuin-A levels over the 6 months was positively cor-
related with the change in TG (r=0.592, p=0.006) and negatively correlated with the change in 
serum globulins (r=-0.523, p=0.018) and CRP (r=-.494, p=0.037). CONCLUSIONS: Circulat-
ing fetuin-A predicted serum triglycerides before as well as 6 months after bariatric surgery.
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INTRODUCTION
Fetuin-A, a plasma glycoprotein, is a negative acute 
phase reactant that is secreted predominantly by the 
liver in adults.1 Fetuin-A regulates calcium metabo-
lism, being an important inhibitor of calcification in 
various tissues, including the vascular wall.2 Another 
reported function of fetuin-A is the induction of insulin 
resistance through the inhibition of insulin receptor 
tyrosine kinase.3 Serum fetuin-A levels have been 
shown to be increased in patients with type 2 diabetes 
mellitus (T2DM) or metabolic syndrome (MetS), as 
well as in the presence of some individual components 
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of MetS.4-6 However, there is an inconsistency in the 
results of the studies investigating the association of 
circulating fetuin-A with each individual component 
of MetS. regarding the relationship of circulating 
fetuin-A with body weight status, although most of 
the studies have found a positive association between 
circulating fetuin-A and body mass index (BMI) and 
a reduction of serum fetuin-A levels after weight loss, 
some studies reported conflicting results.6-16
Bariatric surgery is a weight loss intervention 
achieved via an alteration not only of the passage of 
food through the gastrointestinal tract, but also of the 
secretion of gut hormones regulating appetite.17 Moreo-
ver, among weight loss interventions the magnitude 
of weight reduction after bariatric surgery is by far 
the greatest. Two studies that evaluated the changes 
in circulating fetuin-A after bariatric surgery found 
a decrease in serum fetuin-A levels, with one of the 
studies showing no change in circulating fetuin-A, 
though the exact metabolic role of fetuin-A in this 
context remains to be investigated.14,15,18 The relation-
ship of the changes in circulating fetuin-A with the 
changes in body composition after bariatric surgery 
has not been previously investigated. Although body 
weight (BW) decreases progressively during the 12 
months’ period following bariatric surgery, loss of 
lean body mass (LBM) and reduction of basal meta-
bolic rate (BMr) occur only up until completion of 
the first 6 months without any further decrease in the 
later period.19,20 Therefore, the first 6-month period 
following bariatric surgery represents the period of 
acute change in substrate utilization. The present study 
is a detailed analysis of body composition and a full 
assessment of glycaemic and lipoprotein parameters 
in obese patients undergoing bariatric surgery carried 
out to elucidate the relationship of the changes in 
circulating fetuin-A with the changes in metabolic 
parameters 6 months after bariatric surgery. 
MATERIALS AND METHODS
Subjects
The study was conducted by the Laboratory of 
Physiology of the Medical School of Ioannina Uni-
versity in collaboration with the Obesity Clinic of 
the Diabetic Center and the Second Surgical Clinic 
of Tzaneio General Hospital. The study participants 
were recruited from April 2012 to April 2013. Twenty 
obese subjects (8 men and 12 women) participated in 
the study. They were admitted to the surgical clinic 
to undergo a scheduled bariatric surgery. All patients 
were subjected to laparoscopic sleeve gastrectomy. 
Inclusion criteria for the study were BMI ≥40 kg/
m2 or BMI = 35-40 kg/m2 with obesity-related co-
morbidities. Exclusion criteria were kidney disease, 
liver disease, gastrointestinal disease, neurological 
or psychiatric disorder, hypothyroidism, hyperthy-
roidism, malignancy, use of psychoactive substances 
and history of drug dependence. Lansoprazole 30 mg 
once daily was prescribed to all patients following 
surgery. There were 5 patients with T2DM and stable 
glycaemic control during follow-up who were taking 
the following antidiabetic medications: insulin (2), 
metformin (3), sulfonylureas (1), gliptins (1), thia-
zolidinediones (1), exenatide (1). Six patients had 
arterial hypertension and were taking the following 
antihypertensive medications: angiotensin II recep-
tor antagonists (4), calcium channel blockers (1), 
diuretics (3), beta blockers (1). Five patients were 
under statin treatment. All patients provided written 
informed consent to participate in the study before 
the surgery. The study was approved by the Ethics 
Committee of the Tzaneio General Hospital. 
Anthropometric measurements, body fat assess-
ment and collection of venous blood samples after 
an overnight fast of at least 12 h were performed at 
baseline and 6 months after bariatric surgery. Serum 
samples were stored at -80 °C until analysis.
Body fat measurement
Body composition was assessed by Bioelectrical 
Impedance (BIA). The device used was the tetrapo-
lar scale Tanita BC 418 MA (Tanita Corporation, 
Japan) which provided the BW and a complete body 
composition analysis. The Tanita BC 418 MA is a 
monofrequency BIA analyser which uses the frequency 
of 50 kHz and 8 electrodes integrated in the handles 
and the stepping platform for transmission of a weak 
electrical current through the body. The Tanita BC-
418 MA can show separate body mass readings for 
each upper and lower limb and the trunk with the use 
of 8 polar electrodes. The Tanita formula takes into 
account gender, age, height, BW and distinguishes 
between “athlete” and “non-athlete”. This instrument 
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can provide a complete body composition profile in-
cluding Body Fat Percentage (BF%), Body Fat Mass 
(BFM), BMI, LBM, Estimated Muscle Mass, Total 
Body Water and BMr. All the measurements were 
performed in the morning before breakfast and after 
evacuation of the bladder. Patients were instructed to 
abstain from exercise, alcohol and caffeine during the 
day preceding the measurement of body composition. 
All the measurements were performed before bariatric 
surgery as well as 6 months after surgery.
Fetuin-A measurement
Serum fetuin-A levels were measured using an 
enzyme-linked immunosorbent assay (ELISA) kit 
(BioVendor research and Diagnostic products, Brno, 
Czech republic) with intra-assay CV 2.2-3.6 % and 
inter-assay CV 3.1-6.3 %.
Routine biochemical measurements  
and calculations
Fasting blood samples were analyzed for total 
cholesterol (TC), triglycerides (TG), high-density 
lipoprotein-cholesterol (HDL-C), glucose (Glc), in-
sulin (Ins), glycated haemoglobin (HbA1c), uric 
acid, creatinine (Cre), total proteins (TPr), albu-
min, fibrinogen, C-reactive protein (CrP), thyroid-
stimulating hormone (TSH), free thyroxine (FT4) and 
triiodothyronine (T3), using the standard procedures 
of the biochemistry laboratory of our Hospital. Ho-
meostatic model assessment (HOMA)-index was 
calculated using the formula [fasting insulin (µU/
mL) × fasting glucose (mg/dL)]/405. The quantita-
tive insulin sensitivity check index (QUICKI) was 
calculated using the formula 1 / [log fasting insulin 
(µU/mL) + log fasting glucose (mg/dL)]. Low-density 
lipoprotein cholesterol (LDL-C) was calculated using 
the Friedewald equation [LDL-C = TC - (HDL-C + 
TRG/5)]. Non-HDL-cholesterol (non-HDL-C) was 
calculated as TC - HDL-C. Serum levels of globulins 
were calculated as TPr - serum albumin.
Statistical analysis
All statistical analyses were performed using the 
IBM SPSS Statistics 23.0. The Kolmogorov-Smirnov 
test was used to verify the normality of the distribu-
tions of the parameters. All the studied parameters 
were normally distributed and were expressed as 
means ± SD. The paired t-test, independent t-test 
and Pearson’s correlation analysis were performed 
for normally distributed parameters. The Analysis 
of Variance (ANOVA) test was applied to determine 
whether circulating fetuin-A changed with the num-
ber of factors of MetS at baseline. Linear regression 
analysis was used to identify the independent pre-
dictors of TG at baseline. A two-tailed p <0.05 was 
considered significant.
RESULTS
The characteristics of the patients at baseline and 
after 6 months following bariatric surgery are shown 
in Table 1. The reduction of BW (24.9 ± 9.1%) dur-
ing the 6 months following bariatric surgery was ac-
companied by reduction of BFM, LBM and of both 
systolic blood pressure (SBP) and diastolic blood 
pressure (DBP), as well as by improvement of the 
lipid profile, as indicated by the decrease in TC, TG, 
LDL-C and the increase in HDL-C. Moreover, there 
was a reduction of insulin resistance following bariatric 
surgery, as indicated by the decrease in HOMA-index 
and the increase in QUICKI. TPr decreased during 
this period due to a reduction in serum globulins. The 
number of study participants who had MetS was 15 
at baseline and 6 at 6 months of follow-up.
Comparisons at baseline
Serum fetuin-A levels did not differ between sub-
jects with MetS and those without MetS (p=0.622) 
and did not change with the number of factors of 
MetS (p=0.673) at baseline. Serum fetuin-A levels 
did not differ with regard to the presence of each 
individual component of MetS at baseline, except 
for hypertriglyceridaemia, where increased serum 
fetuin-A levels were found in the presence of this 
component (p=0.011).
Correlation analysis at baseline
The relationship between serum fetuin-A levels and 
various parameters at baseline is shown in Table 2. 
Serum fetuin-A levels were positively correlated with 
TC, TG, LDL-C and non-HDL-C and negatively cor-
related with CrP, TPr and serum globulins at baseline. 
The association of circulating fetuin-A with globulins 
disappeared after adjustment for CrP. The relationship 
between circulating fetuin-A and lipid parameters did 
not change when a subgroup analysis was performed 
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Table 1. The characteristics of the patients (n = 20) at baseline and 
after 6 months of bariatric surgery
Baseline 6 months p  
(6 months  
vs baseline)
Body weight (Kg) 126.1 ± 21.1 94.8 ± 20.8 <0.001
BMI (Kg/m2) 42.5 ± 3.4 32.0 ± 4.8 <0.001
BF% (%) 44.0 ± 6.9 34.7 ± 9.7 <0.001
BFM (Kg) 54.4 ± 10.6 34.7 ± 13.2 <0.001
LBM (Kg) 71.7 ± 16.9 60.1 ± 14.0 <0.001
WC (cm) 125.7 ± 14.2 104.5 ± 17.8 <0.001
SBP (mmHg) 138 ± 14 126 ± 11 <0.001
DBP (mmHg) 87 ± 11 77 ± 8 <0.001
TC (mg/dL) 220 ± 46 189 ± 33 0.010
TG (mg/dL) 132 ± 39 91 ± 29 <0.001
HDL-C (mg/dL) 40 ± 10 47 ± 15 0.045
LDL-C (mg/dL) 137 ± 34 126 ± 22 0.185
nonHDL-C (mg/dL) 180 ± 49 143 ± 22 0.003
Glc (mg/dL) 114 ± 41 98 ± 24 0.039
Ins (μU/mL) 19.3 ± 7.4 12.0 ± 4.7 <0.001
HbA1c (%) 6.5 ± 1.4 5.6 ± 0.9 0.001
HOMA-index 5.6 ± 3.3 3.0 ± 1.8 <0.001
QUICKI 0.305 ± 0.022 0.332 ± 0.024 <0.001
Uric acid (mg/dL) 6.5 ± 1.0 5.3 ± 1.1 <0.001
TPR (mg/dL) 7.3 ± 0.4 6.8 ± 0.5 0.002
Albumin (mg/dL) 4.3 ± 0.3 4.2 ± 0.3 0.392
Globulins (mg/dL) 2.9 ± 0.4 2.6 ± 0.4 0.001
CRP (mg/L) 13.3 ± 8.2 6.5 ± 4.3 <0.001
Fetuin-A (μg/mL) 268.1 ± 53.1 263.8 ± 68.4 0.808
Data are mean ± standard deviation for normally distributed 
variables. The p value refers to the comparison between baseline 
values and those 6 months after bariatric surgery.
Abbreviations: BFM: Body fat mass; BF%: Body fat percentage; 
BMI: Body Mass Index; CrP: C-reactive protein; DBP: Diastolic 
blood pressure; eGFr: Estimated glomerular filtration rate; FT4: 
Free thyroxine; HbA1c: Glycated haemoglobin; HDL-C: High-
density lipoprotein-cholesterol; HOMA-index: Ηomeostasis 
model assessment insulin resistance index; LBM: Lean body 
mass; LDL-C: Low-density lipoprotein-cholesterol; non-HDL-C: 
Non-HDL-cholesterol; QUICKI: Quantitative insulin sensitivity 
check index; Cre: Serum creatinine; Glc: Serum glucose levels; 
Ins: Serum insulin levels; TPr: Serum levels of total proteins; 
SBP: Systolic blood pressure; TSH: Thyroid-stimulating hormone; 
TC: Total cholesterol; TG: Triglycerides; T3: Τriiodothyronine; 
WC: Waist Circumference.
Table 2. The relationship between serum fetuin-A levels and various 
parameters at baseline
r p
Body weight 0.120 0.636
BMI - 0.239 0.340
BF% - 0.151 0.576
BFM - 0.049 0.856
LBM 0.357 0.146
WC 0.268 0.267
SBP - 0.334 0.150
DBP - 0.203 0.391
TC 0.549 0.012
TG 0.461 0.047
HDL-C - 0.036 0.881
LDL-C 0.540 0.012
nonHDL-C 0.524 0.018
HbA1c 0.395 0.105
HOMA-index - 0.229 0.332
QUICKI 0.200 0.399
Uric acid 0.132 0.579
TPr - 0.446 0.049
Albumin 0.181 0.445
Globulins - 0.477 0.033
CrP - 0.604 0.010
Abbreviations: BFM: Body fat mass; BF%: Body fat percent-
age; BMI: Body Mass Index; CrP: C-reactive protein; DBP: 
Diastolic blood pressure; eGFr: Estimated glomerular filtra-
tion rate; FT4: Free thyroxine; HbA1c: Glycated haemoglobin; 
HDL-C: High-density lipoprotein-cholesterol; HOMA-index: 
Ηomeostasis model assessment insulin resistance index; LBM: 
Lean body mass; LDL-C: Low-density lipoprotein-cholesterol; 
non-HDL-C: Non-HDL-cholesterol; QUICKI: Quantitative in-
sulin sensitivity check index; Glc: Serum glucose levels; Ins: 
Serum insulin levels; TPr: Serum levels of total proteins; SBP: 
Systolic blood pressure; TSH: Thyroid-stimulating hormone; 
TC: Total cholesterol; TG: Triglycerides; T3: Τriiodothyronine; 
WC: Waist Circumference.
excluding those taking lipid-lowering drugs. TG was 
positively correlated with WC (r=0.480, p=0.038) and 
tended to be correlated with Glc (r=0.408, p=0.074) at 
baseline, while there was no correlation with BW, BMI, 
BF%, Ins, HOMA-index and QUICKI. We performed 
multiple linear regression analysis to predict TG at 
baseline using as independent variables serum fetuin-
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A levels (β=0.455, p=0.042), WC (β 0.274, p=0.207) 
and Glc (β=0.348, p=0.108). In this model (adjusted 
r2=0.348, p=0.024) serum fetuin-A levels were the 
only variables that independently predicted TG.
Change in circulating fetuin-A  
after 6 months of follow-up
Serum fetuin-A levels did not change during the 
first 6 months following bariatric surgery in the whole 
population (Figure 1). Circulating fetuin-A did not 
change in the subgroup of patients who had MetS 
at baseline and no MetS at 6 months of follow-up 
(p=0.194), nor in the subgroup of patients whose 
number of components of MetS decreased during the 
period of 6 months (p=0.506). Serum fetuin-A levels 
did not change during this period in the subgroups 
of patients who were positive for each individual 
component of MetS at baseline and negative for 
this component at 6 months of follow-up, except for 
hypertriglyceridaemia, where there was a decrease 
in serum fetuin-A levels (p=0.046). A smaller re-
duction of both serum globulins (p=0.003) and CrP 
(p=0.049) was found in the subgroup of patients 
with a decrease in circulating fetuin-A at 6 months 
follow-up compared with those who did not have a 
decrease in circulating fetuin-A.
Correlation analysis during  
the 6 months of follow-up
The relationships between the change in serum 
fetuin-A levels and the changes in various parameters 
after 6 months’ follow-up are shown in Table 3. The 
change in serum fetuin-A levels over this period 
was positively correlated with the change in TG and 
negatively correlated with the change in CrP, TPr 
and serum globulins, while there was a tendency for 
a positive relationship with the change in LBM and 
non-HDL-C. The relationship between the change in 
circulating fetuin-A and the change in TG persisted 
Figure 1. A box plot showing serum fetuin-A levels at baseline 
and 6 months following bariatric surgery. The difference in cir-
culating fetuin-A between these time points was not significant.
Table 3. The relationship between the change in serum fetuin-A levels 
and the changes in various parameters 6 months after bariatric surgery.
r p
Change in body weight 0.288 0.246
Change in BMI 0.235 0.347
Change in BF% 0.114 0.654
Change in BFM 0.082 0.746
Change in LBM 0.411 0.090
Change in WC 0.350 0.168
Change in SBP 0.089 0.708
Change in DBP 0.033 0889
Change in TC 0.307 0.188
Change in TG 0.592 0.006
Change in HDL-C -0.174 0.463
Change in LDL-C 0.167 0.481
Change in nonHDL-C 0.411 0.072
Change in HbA1c -0.071 0.766
Change in HOMA-index -0.258 0.271
Change in QUICKI 0.418 0.075
Change in TPr -0.495 0.026
Change in globulins -0.523 0.018
Change in CrP -0.494 0.037
Abbreviations: BFM: Body fat mass; BFM: Body fat mass; BF%: 
Body fat percentage; BMI: Body Mass Index; CrP: C-reactive pro-
tein; DBP: Diastolic blood pressure; eGFr: Estimated glomerular 
filtration rate; FT4: Free thyroxine; HbA1c: Glycated haemoglobin; 
HDL-C: High-density lipoprotein-cholesterol; HOMA-index: 
Ηomeostasis model assessment insulin resistance index; LBM: 
Lean body mass; LDL-C: Low-density lipoprotein-cholesterol; 
non-HDL-C: Non-HDL-cholesterol; QUICKI: Quantitative in-
sulin sensitivity check index; Glc: Serum glucose levels; Ins: 
Serum insulin levels; TPr: Serum levels of total proteins; SBP: 
Systolic blood pressure; TSH: Thyroid-stimulating hormone; 
TC: Total cholesterol; TG: Triglycerides; T3: Τriiodothyronine; 
WC: Waist Circumference.
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when a subgroup analysis was performed, excluding 
those taking lipid-lowering drugs. After performing 
multiple linear regression analysis, with the change 
in circulating fetuin-A as a dependent variable and 
the changes in TG, CrP, serum globulins and LBM 
as independent variables, only the change in TG was 
significantly correlated with the change in circulating 
fetuin-A (Table 4). The change in TG over 6 months 
after bariatric surgery was not correlated with changes 
in BW, BMI, WC, BF%, Glc, Ins, HOMA-index and 
QUICKI.
DISCUSSION
The present study found that although serum fetuin-
A levels did not change 6 months after bariatric surgery, 
a reduction of circulating fetuin-A occurred more 
frequently in individuals with smaller reduction of 
globulins and CrP. Circulating fetuin-A independently 
predicted serum TG levels in a steady metabolic state, 
as well as 6 months after bariatric surgery.
We demonstrated no relationship of serum fetuin-A 
levels with BMI at baseline. The previously reported 
positive association of circulating fetuin-A with BMI 
referred to populations with a wide range of BMI, 
including not only obese patients, but also lean or 
overweight individuals.6-9 Thus, the fact that our study 
only evaluated subjects with BMI ≥35 kg/m2 may 
have limited the potential for detection of significant 
associations between circulating fetuin-A and indices 
of obesity across the relatively narrow range of BMI 
of our study. Similarly, Himmetoglu et al found that 
although circulating fetuin-A was higher in morbidly 
obese patients compared with lean or overweight con-
trols, it was not correlated with BMI in the subgroup 
of morbidly obese individuals.21 Moreover, the small 
number and the heterogeneity of the participants of 
our study may have further contributed to the absence 
of any association between circulating fetuin-A and 
indices of obesity. The positive association of circulat-
ing fetuin-A with BMI has been reported in studies 
with at least an 8 times greater number of participants 
compared with our study. The previously reported 
positive association of circulating fetuin-A levels with 
BMI is possibly causal, as indicated by the fact that 
mice null for the fetuin-A gene had lower BW and 
were more resistant to weight gain after a high-fat 
diet compared with wild type mice.22,23
The present study showed that serum fetuin-A levels 
did not change after 6 months of weight loss following 
bariatric surgery. This finding is consistent with the 
results of the study of Kahraman et al.18 Two other 
studies evaluated the changes in circulating fetuin-A 
at least 12 months after bariatric surgery.14,15 These 
studies found a decrease in serum fetuin-A levels at 
least 12 months after bariatric surgery.14,15 However, the 
abovementioned 3 studies did not perform an analysis 
of body composition. Interestingly, the change in 
circulating fetuin-A tended to be positively correlated 
with the change in LBM in our study, implying that 
a more negative nitrogen balance associated with a 
greater loss of LBM may downregulate the production 
of glycoprotein fetuin-A by the liver. Furthermore, the 
present study found that serum fetuin-A levels were 
negatively correlated with both serum globulins and 
CrP at baseline as well as 6 months after bariatric 
surgery. Weight loss is known to reduce CrP, pos-
sibly indicating a decrease in adipose tissue-induced 
inflammation.24 In this context, the downregulation of 
positive acute phase reactants after weight reduction 
is expected to be accompanied by an upregulation 
of circulating fetuin-A, which, as mentioned above, 
Table 4. Multiple linear regression analysis with the change in circulating fetuin-A as dependent variable
Dependent variable Independent  
variables
Standardized 
β coefficient
p value for each
independent variable
Adjusted R2 
for the model
p value  
for the model
Change in fetuin-A Change in TG 0.499 0.030 0.271 0.066
Change in CrP 0.045 0.824
Change in globulins - 0.271 0.212
Change in LBM 0.102 0.614
Abbreviations: CrP: C-reactive protein; LBM: Lean body mass; TG: Triglycerides.
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is a negative acute phase reactant.1 Consistently, 
a smaller reduction of both serum globulins and 
CrP after bariatric surgery predicted a decrease in 
circulating fetuin-A in our study. The serum levels 
of globulins in our study possibly reflect the obesity-
related low-grade inflammation, as indicated by the 
value of CrP. Hence, the property of fetuin-A as a 
negative acute phase reactant may have hindered the 
demonstration of a decrease in circulating fetuin-A 
after bariatric surgery in our study. This furnishes a 
plausible explanation for the absence of a decrease 
in circulating fetuin-A in the whole population of the 
present study. These considerations should be taken 
into account in the design of future studies investigat-
ing the metabolic role of fetuin-A, as well as in the 
interpretation of their results.
We found that among patients with BMI ≥35 kg/
m2 serum fetuin-A levels did not differ between those 
with MetS and those without MetS. The majority of 
studies have shown circulating fetuin-A to be upregu-
lated in the presence of MetS among individuals with 
a wide range of BMI.6,9,25,26 However, the comparison 
between individuals with MetS and no MetS appears to 
be influenced by obesity.27 Indeed, patients with BMI 
≥35 kg/m2 always fulfill the WC criteria of MetS, as 
demonstrated in our study.27,28 The latter individuals 
need to fulfill only 2 criteria of the remaining 4 to be 
diagnosed with MetS, lowering the threshold for the 
diagnosis of MetS in these patients and thus limiting 
the differences between the subjects with MetS and 
patients without MetS.27 In this context, circulating 
fetuin-A may not have enough power to discrimi-
nate between MetS and non-MetS in patients with 
BMI ≥35 kg/m2. Importantly, increased TG was the 
only component of MetS that was determined in our 
study by circulating fetuin-A at baseline, as well as 6 
months after bariatric surgery. Indeed, increased TG 
appears to be the component of MetS with the most 
consistent association with serum fetuin-A levels in 
a steady metabolic state.6,29
Our study demonstrated a positive relationship 
between serum levels of fetuin-A and TG at baseline 
as well as 6 months after bariatric surgery. Likewise, 
in the majority of studies serum TG levels have been 
reported to increase with increasing serum fetuin-A 
levels in a steady metabolic state.6,30-32 Furthermore, 
a fall in serum fetuin-A levels has been shown after 
administration of TG-lowering medications, such 
as fenofibrate, n-3 polyunsaturated fatty acids and 
niacin.33-35 Kaushik et al reported that the niacin-
induced change in circulating fetuin-A was positively 
correlated with the change in TG.35 However, the 
relationship of the change in circulating fetuin-A with 
the change in TG during a weight loss intervention 
has not been previously investigated. The relation-
ship between fetuin-A and TG is possibly causal, as 
indicated by the reported acceleration of exogenous 
fatty acid incorporation into cellular TG by fetuin-A.36 
Further studies are needed to confirm the presumed 
fetuin-A-induced upregulation of TG and elucidate 
the specific underlying mechanisms. Importantly, our 
study found for the first time that circulating fetuin-A 
was the only independent predictor of serum TG at 
baseline, implying a possible important role of fetuin-
A in upregulating serum TG independently of all the 
traditional metabolic factors.
The current study found that circulating fetuin-A 
was positively correlated with non-HDL-C at baseline 
and the change in circulating fetuin-A tended to be 
positively correlated with the change in non-HDL-
C after 6 months of follow-up. With regard to the 
relationship between serum levels of fetuin-A and 
LDL-C, a positive association was demonstrated only 
at baseline, but not during the 6 months of follow-up. 
The fact that a few patients were taking statins may 
have contributed to these negative results. A positive 
relationship of serum fetuin-A levels with both LDL-
C and non-HDL-C has previously been shown in a 
steady metabolic state.6,30,31,37 However, the evaluation 
of the associations between the change in circulating 
fetuin-A and the changes in LDL-C and non-HDL-C 
during an intervention has not been performed before. 
The data of our study indicate the possible existence 
of a link between fetuin-A and the metabolism of 
ApoB-containing lipoproteins. This issue requires 
further investigation.
The results of our study should be interpreted in 
light of some limitations. Firstly, the small number 
of patients will have decreased the possibility of de-
tecting significant changes in serum fetuin-A levels 
during follow-up, as well as significant associations 
of serum fetuin-A levels with metabolic parameters. 
This was true especially regarding subgroup analysis. 
Secondly, the study population was heterogeneous, 
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situations that may have influenced serum fetuin-A 
levels. However, these relationships did not change 
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histology to determine if there was a relationship of 
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CONCLUSIONS
The current study found that serum fetuin-A levels 
independently predicted serum triglycerides before as 
well as during the first 6 months following bariatric 
surgery. Further well-designed studies are needed 
to confirm these results and investigate whether the 
relationship between fetuin-A and triglyceride me-
tabolism is causal in humans.
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